For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

There is also an oral GLP-1 RA peptide called MET-002, a product of Metsera’s platform for optimizing the oral delivery of ...

Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

initiated an SGLT-2 inhibitor or glucagon-like peptide-1 receptor agonist (GLP-1 RA), with a dipeptidyl peptidase-4 (DPP-4) ...

Metsera has raised over $500 million to date. Highly competitive, clinical-stage portfolio accelerating Phase 2 trials of ultra-long acting, fully-biased injectable GLP-1 RA underway Metsera recently ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...